Revenue and Expenses - AgeX recognized revenues of $9,000 and $19,000 for the three and six months ended June 30, 2023, respectively, compared to $12,000 and $17,000 for the same periods in 2022, indicating a revenue decrease of approximately 25% for the three-month period [166]. - Cost of sales for the three and six months ended June 30, 2023, were $5,000 and $6,000, respectively, down from $6,000 and $7,000 in the same periods of 2022, reflecting a decrease of 16.67% for the three-month period [167]. - Research and development expenses decreased by approximately $0.1 million to $0.16 million for the three months ended June 30, 2023, a 38.2% decrease compared to $0.26 million in 2022 [169]. - General and administrative expenses increased by $0.4 million to $1.7 million for the three months ended June 30, 2023, a 29.3% increase compared to $1.3 million in 2022 [171]. - Total other expense, net for the three months ended June 30, 2023, was $1 million, primarily due to amortization of deferred debt issuance costs [175]. Financial Position and Cash Flow - AgeX incurred an accumulated deficit of $122.2 million as of June 30, 2023, and expects to continue incurring operating losses and negative cash flows [181]. - Net cash used in operating activities for the six months ended June 30, 2023, was $3.9 million, with a net loss attributable to the company of $6 million [190]. - Cash flows from investing activities included a $10 million loan made to Serina during the six months ended June 30, 2023 [191]. - Financing activities provided net cash of $13.5 million, entirely from credit facilities drawn from Juvenescence during the same period [192]. - The difference between net loss and cash used in operating activities was primarily due to non-cash items totaling $2.1 million [190]. - The company may need to modify or suspend operations if financing is unavailable or inadequate [188]. Strategic Initiatives - AgeX is pursuing a potential merger with Serina, which has not yet been finalized or approved by either company's board of directors [160][161]. - The company plans a potential spinoff of its subsidiary Reverse Bio, which would become a separate publicly traded company if completed [160]. - The company has made adjustments to its operating plans to reduce projected cash expenditures, including downsizing its leased office space and workforce [182]. - Operating expenses were reduced by outsourcing research and development, but this has hindered progress in developing target product candidates and technologies [186]. Operational Challenges - The company faced uncertainty regarding the impact of the COVID-19 pandemic on financing availability and overall operations [187]. - The ongoing pandemic's impact on business results remains highly uncertain and difficult to predict [187]. - There were no changes in internal control over financial reporting that materially affected the company's controls [194]. - The company is not currently involved in any material litigation or proceedings [196].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol Name of exchange on which registered Common Stock, par value $0.0001 per share AGE NYSE American FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number 1-38519 AgeX Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 82-1436829 (State or other j ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-Q For the transition period from ___________ to ___________ Commission file number 1-38519 AgeX Therapeutics, Inc. (Exact name of registrant as specified in its charter) Washington, D.C. 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Address of principal execut ...

Financial Performance - Total revenues for the three months ended June 30, 2022, were $12,000, a decrease of 67.6% compared to $37,000 for the same period in 2021[22]. - Net loss attributable to AgeX for the six months ended June 30, 2022, was $5,324,000, compared to a net loss of $4,562,000 for the same period in 2021, representing an increase of 16.7%[22]. - The company reported a gross profit of $6,000 for the three months ended June 30, 2022, compared to $24,000 for the same period in 2021, a decline of 75%[22]. - AgeX recognized a gain of $106,000 from the deconsolidation of LifeMap Sciences, which is reported as a taxable transaction resulting in a taxable loss[92]. - The accumulated deficit as of June 30, 2022 was $111.1 million, indicating ongoing operating losses and negative cash flows since inception[185]. Cash and Liquidity - Cash and cash equivalents increased to $702,000 as of June 30, 2022, from $584,000 as of December 31, 2021, reflecting a growth of 20.2%[20]. - AgeX's cash and cash equivalents were $0.7 million as of June 30, 2022, which, along with a potential additional loan of $3.0 million, may not be sufficient to meet its funding requirements for the next twelve months[38]. - AgeX's total cash, cash equivalents, and restricted cash amounted to $752,000 as of June 30, 2022, compared to $634,000 as of December 31, 2021[56]. - Net cash used in operating activities from continuing operations for the six months ended June 30, 2022, was $3,382,000, compared to $4,234,000 for the same period in 2021, a decrease of 20.1%[28]. - The company expects to continue incurring operating losses and negative cash flows, raising substantial doubt about its ability to continue as a going concern[186]. Expenses - Research and development expenses for the three months ended June 30, 2022, were $259,000, a decrease of 46.1% from $481,000 for the same period in 2021[22]. - General and administrative expenses for the six months ended June 30, 2022, were $2,998,000, down 20.5% from $3,770,000 for the same period in 2021[22]. - AgeX incurred approximately $11,000 and $57,000 of allowable expenses under the NIH grant for the three and six months ended June 30, 2021, respectively[68]. - Total other expense, net for the six months ended June 30, 2022 was $1.7 million, consisting of $1.4 million amortization of deferred debt issuance costs and $0.3 million unrealized loss on warrants[179]. - For the six months ended June 30, 2022, stock-based compensation expense totaled $437,000, compared to $464,000 for the same period in 2021[141]. Debt and Financing - AgeX had drawn the full $8.0 million line of credit under the 2020 Loan Agreement, with the outstanding principal balance due on March 30, 2023[98]. - AgeX has drawn $10,160,000 from a $13,160,000 line of credit under the Secured Convertible Promissory Note, with an outstanding principal balance due on February 14, 2024[101]. - The company may sell up to $12.1 million of additional shares of common stock in "at-the-market" transactions to raise capital[188]. - AgeX's total debt balances net of issuance costs amounted to $18.63 million, with debt issuance costs totaling $7.92 million[120]. - The company faces challenges in obtaining necessary capital due to ongoing net operating losses and debt obligations to Juvenescence[203]. Stock and Equity - The weighted average number of common shares outstanding for the three months ended June 30, 2022, was 37,943,000, compared to 37,936,000 for the same period in 2021[22]. - As of June 30, 2022, AgeX had 37,945,108 shares of common stock issued and outstanding, an increase from 37,941,220 shares at December 31, 2021[132]. - AgeX issued warrants to purchase 6,502,442 shares of common stock in connection with $10,160,000 of drawdowns from Juvenescence under the Secured Note during the six months ended June 30, 2022[133]. - AgeX's stockholders' equity was reported to be less than $2,000,000, leading to a deficiency letter from the NYSE American regarding continued listing standards[156]. - AgeX regained compliance with the NYSE American's continued listing standards on April 15, 2021, but remains subject to normal continued listing monitoring[157]. Operational Changes - The company has initiated staff reductions and eliminated laboratory facilities to reduce operating expenses amid the COVID-19 pandemic[39]. - The company has deferred in-house development of its product candidates and technologies due to staffing reductions and the closing of research laboratory facilities[203]. - AgeX's operations and financial results may be impacted by the ongoing COVID-19 pandemic, with uncertainty regarding the duration and scope of its effects[167]. - The ongoing COVID-19 pandemic may adversely impact the availability of financing and disrupt operations, adding to the uncertainty of future capital needs[190]. - The company is exploring options for obtaining additional capital, including the sale of common stock and collaborative research arrangements[203]. Research and Development - AgeX plans to finance its iTR research and development through its subsidiary Reverse Bioengineering, Inc.[46]. - AgeX's research and development expenses consist primarily of personnel costs, stock-based compensation, and outside consultants[72]. - Research and development expenses for the six months ended June 30, 2022 were $0.7 million, reflecting a focus on outsourcing rather than internal development[192]. - The company has a Sponsored Research Agreement with the University of California at Irvine for the derivation of neural stem cells, with initial work expected to conclude during 2022[166]. - AgeX does not expect to earn subscription and advertising revenues in subsequent accounting periods due to the LifeMap Deconsolidation[65].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number 1-38519 AgeX Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 82-1436829 (State or ot ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission file number 1-38519 AgeX Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorp ...

[PART I — FINANCIAL INFORMATION](index=3&type=section&id=PART%201%20%E2%80%94%20FINANCIAL%20INFORMATION) This section presents the company's core financial statements and management's discussion and analysis of its financial condition and operational results [Item 1. Financial Statements](index=5&type=section&id=Item%201.%20Financial%20Statements) The financial statements reveal a net loss of $6.5 million and a $10.0 million stockholders' deficit, with critical liquidity dependent on Juvenescence loans [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets decreased to $2.4 million, liabilities rose to $12.4 million, and stockholders' deficit worsened to $10.0 million Condensed Consolidated Balance Sheet Highlights (in thousands) | Balance Sheet Item | Sep 30, 2021 (Unaudited) (in thousands) | Dec 31, 2020 (in thousands) | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $731 | $527 | | Total current assets | $1,475 | $2,283 | | TOTAL ASSETS | $2,427 | $3,925 | | **Liabilities & Stockholders' Deficit** | | | | Total current liabilities | $6,598 | $5,357 | | Loan due to Juvenescence (Total) | $11,407 | $5,860 | | TOTAL LIABILITIES | $12,405 | $9,321 | | Total stockholders' deficit | ($9,978) | ($5,396) | | TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT | $2,427 | $3,925 | [Condensed Consolidated Statements of Operations](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Q3 2021 revenues were minimal at $24,000, with net loss from continuing operations improving to $2.0 million due to expense reductions Q3 2021 vs Q3 2020 Statement of Operations (in thousands, except per share data) | Metric | Q3 2021 (in thousands) | Q3 2020 (in thousands) | | :--- | :--- | :--- | | Total revenues | $24 | $69 | | Research and development | $275 | $653 | | General and administrative | $1,421 | $1,796 | | Loss from operations | ($1,674) | ($2,397) | | Net Loss from Continuing Operations | ($1,955) | ($2,524) | | Net Loss Attributable to AgeX | ($1,955) | ($2,543) | | Net Loss Per Share (Basic & Diluted) | ($0.05) | ($0.07) | Nine Months 2021 vs 2020 Statement of Operations (in thousands, except per share data) | Metric | Nine Months 2021 (in thousands) | Nine Months 2020 (in thousands) | | :--- | :--- | :--- | | Total revenues | $117 | $203 | | Research and development | $1,080 | $2,809 | | General and administrative | $5,191 | $5,146 | | Gain on deconsolidation of LifeMap Sciences | $106 | $0 | | Loss from operations | ($6,066) | ($7,773) | | Net Loss from Continuing Operations | ($6,423) | ($7,989) | | Net Loss Attributable to AgeX | ($6,517) | ($8,419) | | Net Loss Per Share (Basic & Diluted) | ($0.17) | ($0.22) | [Condensed Consolidated Statements of Cash Flows](index=9&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operations was $6.2 million, offset by $6.0 million from financing activities, primarily Juvenescence loans Cash Flow Summary for Nine Months Ended Sep 30 (in thousands) | Cash Flow Activity | 2021 (in thousands) | 2020 (in thousands) | | :--- | :--- | :--- | | Net cash used in operating activities | ($6,208) | ($6,197) | | Net cash provided by (used in) investing activities | $416 | ($20) | | Net cash provided by financing activities | $5,996 | $4,969 | | **Net Increase (Decrease) in Cash** | **$204** | **($1,245)** | - Financing activities were the primary source of cash, with **$5.5 million** drawn from the Juvenescence loan facility and approximately **$496,000** raised from the issuance of common stock[28](index=28&type=chunk) - Investing activities were primarily impacted by the receipt of **$466,000** from the sale of LifeMap Sciences[28](index=28&type=chunk) [Notes to Financial Statements](index=10&type=section&id=Notes%20to%20Financial%20Statements) Notes reveal a 'Going Concern' warning, heavy reliance on Juvenescence loans, and the disposition of LifeMap Sciences - The company has substantial doubt about its ability to continue as a going concern, as its cash of **$0.7 million** and available loan facilities are not sufficient to fund operations for the next twelve months[36](index=36&type=chunk) - On March 15, 2021, AgeX disposed of its majority-owned subsidiary LifeMap Sciences in a cash-out merger. AgeX received approximately **$466,400** in cash. The results of LifeMap are now reported as discontinued operations[11](index=11&type=chunk)[12](index=12&type=chunk)[13](index=13&type=chunk) - AgeX is financed primarily through loans from its largest stockholder, Juvenescence. As of September 30, 2021, AgeX had borrowed **$5.5 million** under the 2019 Loan Agreement and **$7.5 million** under the 2020 Loan Agreement[90](index=90&type=chunk)[98](index=98&type=chunk)[100](index=100&type=chunk) - A Paycheck Protection Program (PPP) loan of **$432,952** obtained in April 2020 was forgiven in full in February 2021[132](index=132&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)](index=32&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) MD&A highlights critical financial condition, dependence on Juvenescence, and significant reductions in R&D and G&A expenses [Results of Operations](index=33&type=section&id=Results%20of%20Operations) Q3 2021 revenues declined by 65.2%, while R&D and G&A expenses decreased by 57.9% and 20.9% respectively Operating Expense Changes (in thousands) | Expense Category | Q3 2021 (in thousands) | Q3 2020 (in thousands) | $ Change (in thousands) | % Change | | :--- | :--- | :--- | :--- | :--- | | Research and development | $275 | $653 | ($378) | (57.9)% | | General and administrative | $1,421 | $1,796 | ($375) | (20.9)% | | **Total Operating Expenses** | **$1,696** | **$2,449** | **($753)** | **(30.7)%** | - The decrease in R&D expenses is attributed to scaled-down activities following the layoff of **11 employees** in May 2020 and the shutdown of lab facilities as of December 31, 2020[153](index=153&type=chunk) - Other income in 2021 primarily consists of a **$437,000** gain recognized upon the forgiveness of the company's PPP Loan in February 2021[159](index=159&type=chunk) [Liquidity and Capital Resources](index=36&type=section&id=Liquidity%20and%20Capital%20Resources) Substantial doubt exists about going concern, with an accumulated deficit of $103.6 million and insufficient funding for the next twelve months - Management states that cash, cash equivalents, and available loan facilities are not sufficient to satisfy operating requirements for the next twelve months, raising substantial doubt about the company's ability to continue as a going concern[165](index=165&type=chunk) - As of September 30, 2021, the company had an accumulated deficit of **$103.6 million** and expects to continue incurring operating losses and negative cash flows[164](index=164&type=chunk) - During the nine months ended September 30, 2021, the company drew **$5.5 million** from its loan agreements with Juvenescence and raised approximately **$496,000** in gross proceeds from its at-the-market (ATM) stock offering[174](index=174&type=chunk) [PART II — OTHER INFORMATION](index=40&type=section&id=PART%20II%20%E2%80%94%20OTHER%20INFORMATION) This section details the company's updated risk factors, particularly regarding its going concern status, and its equity sales activities [Item 1A. Risk Factors](index=40&type=section&id=Item%201A.%20Risk%20Factors) The primary risk factor update emphasizes substantial doubt about the company's ability to continue as a going concern - The company explicitly states that its cash, available credit, and potential proceeds from its ATM offering are not sufficient to satisfy funding requirements for the next twelve months, raising substantial doubt about its ability to continue as a going concern[184](index=184&type=chunk) - The company had an accumulated deficit of **$103.6 million** as of September 30, 2021, and expects continued operating losses and negative cash flows[185](index=185&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=40&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company generated approximately $480,790 in net proceeds from its at-the-market stock offering for working capital At-the-Market (ATM) Offering Activity (Nine Months Ended Sep 30, 2021) | Metric | Amount (USD) | | :--- | :--- | | Shares Sold | 242,200 | | Gross Proceeds | $495,708 | | Total Expenses | $14,918 | | Net Proceeds | ~$480,790 | - The net proceeds from the ATM offering were used for working capital, including payments for professional fees, insurance premiums, consulting fees, and director compensation[192](index=192&type=chunk)

PART I — FINANCIAL INFORMATION [Forward-Looking Statements](index=3&type=section&id=Forward-Looking%20Statements) This section highlights that the report contains forward-looking statements, involving known and unknown risks and uncertainties that could cause actual results to differ materially from projections, with no obligation for the company to update them - All statements other than historical facts are **forward-looking**, identifiable by specific keywords[7](index=7&type=chunk) - Forward-looking statements are subject to known and unknown **risks, uncertainties, and other factors** that may cause actual results to differ materially from expectations[8](index=8&type=chunk) - The company assumes **no obligation to update or revise** these forward-looking statements, even with new information[8](index=8&type=chunk) [Disposition and Deconsolidation of LifeMap Sciences, Inc. (Overview)](index=4&type=section&id=Disposition%20and%20Deconsolidation%20of%20LifeMap%20Sciences%2C%20Inc.%20%28Overview%29) AgeX Therapeutics completed the merger and deconsolidation of LifeMap Sciences, Inc. on March 15, 2021, receiving **$466,400 in cash** and converting **$1,761,296 of debt** into common stock, ceasing its subsidiary status - AgeX completed the merger of LifeMap Sciences, Inc. on **March 15, 2021**, with Atlas Capital Partners Limited becoming the sole shareholder[11](index=11&type=chunk) Merger Consideration Received by AgeX | Item | Amount ($) | | :------------------------------------------------ | :----------- | | Cash received as pro rata share of Merger Consideration | 466,400 | | LifeMap Sciences' indebtedness converted to common stock | 1,761,296 | | Cash payment for portion of indebtedness not converted | 250,000 | - LifeMap Sciences' results of operations and cash flows are reported as **discontinued operations** for all periods in AgeX's condensed consolidated financial statements[13](index=13&type=chunk) [Item 1. Financial Statements](index=5&type=section&id=Item%201.%20Financial%20Statements) This section presents AgeX Therapeutics, Inc.'s unaudited condensed consolidated financial statements, including balance sheets, statements of operations, comprehensive loss, and cash flows for specified periods [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) This section provides a detailed overview of AgeX Therapeutics' financial position through its condensed consolidated balance sheets Condensed Consolidated Balance Sheets (in thousands) | Item | June 30, 2021 (Unaudited) | December 31, 2020 | | :--------------------------------------- | :------------------------ | :------------------ | | **ASSETS** | | | | Total current assets | $1,556 | $2,283 | | Total assets | $2,541 | $3,925 | | **LIABILITIES AND STOCKHOLDERS' DEFICIT** | | | | Total current liabilities | $5,271 | $5,357 | | Total liabilities | $10,835 | $9,321 | | Total stockholders' deficit | $(8,294) | $(5,396) | - Total assets **decreased by approximately 35.3%** from **$3,925 thousand** at December 31, 2020, to **$2,541 thousand** at June 30, 2021[21](index=21&type=chunk) - Total stockholders' deficit **increased by approximately 53.7%** from **$(5,396) thousand** at December 31, 2020, to **$(8,294) thousand** at June 30, 2021, indicating a worsening financial position[21](index=21&type=chunk) [Condensed Consolidated Statements of Operations](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) This section presents AgeX Therapeutics' financial performance through its condensed consolidated statements of operations, detailing revenues, expenses, and net loss Condensed Consolidated Statements of Operations (in thousands, except per share data) | Item | Three Months Ended June 30, 2021 | Three Months Ended June 30, 2020 | Six Months Ended June 30, 2021 | Six Months Ended June 30, 2020 | | :------------------------------------------------ | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Total revenues | $37 | $45 | $93 | $134 | | Gross profit | $24 | $42 | $77 | $130 | | Total operating expenses | $2,229 | $2,410 | $4,575 | $5,506 | | Gain on deconsolidation of LifeMap Sciences | $- | $- | $106 | $- | | Loss from continuing operations | $(2,475) | $(2,432) | $(4,468) | $(5,465) | | Loss from discontinued operations | $- | $(299) | $(103) | $(488) | | NET LOSS | $(2,475) | $(2,731) | $(4,571) | $(5,953) | | NET LOSS ATTRIBUTABLE TO AGEX | $(2,474) | $(2,689) | $(4,562) | $(5,876) | | NET LOSS PER COMMON SHARE (BASIC AND DILUTED) | $(0.07) | $(0.07) | $(0.12) | $(0.16) | - Net loss attributable to AgeX **decreased by 8.0%** for the three months and **22.4%** for the six months ended June 30, 2021, primarily due to a gain on deconsolidation and reduced operating expenses[23](index=23&type=chunk) - Loss from discontinued operations significantly **decreased to $0** for Q2 2021 and **$(103) thousand** for H1 2021, following LifeMap Sciences' deconsolidation[23](index=23&type=chunk) [Condensed Consolidated Statements of Comprehensive Loss](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Comprehensive%20Loss) This section outlines AgeX Therapeutics' comprehensive loss, including net loss and other comprehensive income/loss items, for the reported periods Condensed Consolidated Statements of Comprehensive Loss (in thousands) | Item | Three Months Ended June 30, 2021 | Three Months Ended June 30, 2020 | Six Months Ended June 30, 2021 | Six Months Ended June 30, 2020 | | :------------------------------------------------ | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | NET LOSS | $(2,475) | $(2,731) | $(4,571) | $(5,953) | | Foreign currency translation adjustments from discontinued operations | $- | $37 | $(143) | $12 | | COMPREHENSIVE LOSS | $(2,475) | $(2,694) | $(4,714) | $(5,941) | | COMPREHENSIVE LOSS ATTRIBUTABLE TO AGEX COMMON STOCKHOLDERS | $(2,474) | $(2,652) | $(4,705) | $(5,864) | - Comprehensive loss attributable to AgeX common stockholders **decreased by 6.7%** for the three months and **19.7%** for the six months ended June 30, 2021, compared to prior year periods[24](index=24&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) This section details AgeX Therapeutics' cash inflows and outflows from operating, investing, and financing activities for the reported periods Condensed Consolidated Statements of Cash Flows (in thousands) | Item | Six Months Ended June 30, 2021 | Six Months Ended June 30, 2020 | | :------------------------------------------------ | :----------------------------- | :----------------------------- | | Net cash used in operating activities | $(4,324) | $(4,308) | | Net cash provided by (used in) investing activities | $416 | $(8) | | Net cash provided by financing activities | $3,996 | $2,992 | | NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | $88 | $(1,319) | | Cash, cash equivalents and restricted cash at end of period | $665 | $1,133 | - Net cash provided by investing activities significantly **improved to $416 thousand** in H1 2021 from **$(8) thousand** in H1 2020, primarily due to proceeds from LifeMap Sciences' sale[27](index=27&type=chunk) - Net cash provided by financing activities **increased by 33.6% to $3,996 thousand** in H1 2021, driven by higher loan drawdowns from Juvenescence and common stock issuance proceeds[27](index=27&type=chunk) - The company experienced a net increase in cash, cash equivalents, and restricted cash of **$88 thousand** in H1 2021, a significant improvement from a net decrease of **$(1,319) thousand** in H1 2020[27](index=27&type=chunk) [Notes to Condensed Consolidated Interim Financial Statements](index=10&type=section&id=Notes%20to%20Condensed%20Consolidated%20Interim%20Financial%20Statements) This section provides detailed notes to the condensed consolidated interim financial statements, covering organization, liquidity, accounting policies, LifeMap Sciences' disposition, balance sheet components, related party transactions, equity, stock-based awards, income taxes, cash flow, commitments, contingencies, and subsequent events [1. Organization, Business Overview and Liquidity](index=10&type=section&id=1.%20Organization%2C%20Business%20Overview%20and%20Liquidity) This section outlines AgeX Therapeutics' business, its focus on therapeutics for aging and degenerative diseases, and its ongoing liquidity challenges and going concern issues - AgeX Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics for **human aging and degenerative diseases** using telomerase-mediated cellular immortality and regenerative biology[30](index=30&type=chunk)[31](index=31&type=chunk) - AgeX has incurred operating losses and negative cash flows since inception, with an **accumulated deficit of $101.6 million** as of June 30, 2021, raising substantial doubt about its **going concern** ability[35](index=35&type=chunk)[36](index=36&type=chunk) - The company implemented **staff reductions** in April 2020 and eliminated its laboratory facilities lease by December 31, 2020, to reduce cash expenditures and extend operations[37](index=37&type=chunk)[38](index=38&type=chunk) - AgeX's ability to raise additional capital is **uncertain** and may be adversely impacted by the COVID-19 pandemic, potentially forcing operational modifications, curtailments, delays, or suspensions[39](index=39&type=chunk) [2. Basis of Presentation and Summary of Significant Accounting Policies](index=12&type=section&id=2.%20Basis%20of%20Presentation%20and%20Summary%20of%20Significant%20Accounting%20Policies) This section details the basis of financial statement presentation and summarizes AgeX Therapeutics' significant accounting policies, including revenue recognition and recent accounting standard adoptions - The condensed consolidated interim financial statements are prepared in accordance with **GAAP** for interim financial information, with certain disclosures condensed or omitted[40](index=40&type=chunk) - AgeX consolidates its direct and indirect wholly-owned or majority-owned subsidiaries, reflecting **noncontrolling interest** as a separate element of stockholders' deficit[42](index=42&type=chunk)[46](index=46&type=chunk) - Revenue recognition follows a **five-step approach under Topic 606**; LifeMap Sciences' subscription and advertisement revenues were a major source prior to deconsolidation, now discontinued[49](index=49&type=chunk)[52](index=52&type=chunk) - Grant revenues, primarily from NIH, are recognized when related costs are incurred and the right to payment is realized, as government entities do not meet the definition of a 'customer' under Topic 606[53](index=53&type=chunk)[54](index=54&type=chunk) - AgeX adopted **ASU 2019-12 (Income Taxes)** and **ASU 2020-06 (Debt with Conversion and Other Options)** as of January 1, 2021, with no material impact on its consolidated financial statements[71](index=71&type=chunk)[72](index=72&type=chunk) [3. Disposition and Deconsolidation of LifeMap Sciences](index=20&type=section&id=3.%20Disposition%20and%20Deconsolidation%20of%20LifeMap%20Sciences) This section details the financial impact of AgeX Therapeutics' disposition and deconsolidation of LifeMap Sciences, including cash received and the gain recognized - AgeX completed the cash-out merger of LifeMap Sciences on **March 15, 2021**, receiving **$466,400 in cash** and converting **$1,761,296 of debt** into LifeMap Sciences common stock[78](index=78&type=chunk)[79](index=79&type=chunk) LifeMap Sciences Operating Results (Discontinued Operations, in thousands) | Item | Three Months Ended June 30, 2021 | Three Months Ended June 30, 2020 | Six Months Ended June 30, 2021 | Six Months Ended June 30, 2020 | | :------------------------------------------------ | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Net revenues | $- | $369 | $277 | $795 | | Loss from discontinued operations | $- | $(299) | $(103) | $(488) | | Net loss from discontinued operations attributable to noncontrolling interest | $- | $41 | $7 | $76 | | Loss from discontinued operations attributable to AgeX | $- | $(258) | $(96) | $(412) | - AgeX recognized a **gain of $106,000** from the LifeMap Deconsolidation, which resulted in a taxable loss, thus no income tax was due[86](index=86&type=chunk) [4. Selected Balance Sheet Components](index=22&type=section&id=4.%20Selected%20Balance%20Sheet%20Components) This section provides a breakdown of selected balance sheet components, including property and equipment, intangible assets, and accounts payable and accrued liabilities - Property and equipment of **$381,000** were fully depreciated at June 30, 2021, and December 31, 2020[87](index=87&type=chunk) Intangible Assets, Net (in thousands) | Item | June 30, 2021 (Unaudited) | December 31, 2020 | | :-------------------------- | :------------------------ | :------------------ | | Intangible assets | $1,312 | $5,586 | | Accumulated amortization | $(377) | $(3,994) | | Total intangible assets, net | $935 | $1,592 | - Intangible assets, net, **decreased by 41.3%** from **$1,592 thousand** at December 31, 2020, to **$935 thousand** at June 30, 2021, primarily due to the LifeMap Deconsolidation[88](index=88&type=chunk)[89](index=89&type=chunk) Accounts Payable and Accrued Liabilities (in thousands) | Item | June 30, 2021 (Unaudited) | December 31, 2020 | | :-------------------------------- | :------------------------ | :------------------ | | Accounts payable | $483 | $761 | | Accrued compensation | $197 | $228 | | Accrued vendors and other expenses | $622 | $667 | | Total accounts payable and accrued liabilities | $1,302 | $1,656 | [5. Related Party Transactions](index=22&type=section&id=5.%20Related%20Party%20Transactions) This section details AgeX Therapeutics' financial arrangements and transactions with related parties, primarily Juvenescence, its largest stockholder - AgeX secured convertible facility agreements with Juvenescence, its largest stockholder, providing lines of credit totaling **$8.0 million** and **$2.0 million**[92](index=92&type=chunk)[96](index=96&type=chunk) - As of June 30, 2021, AgeX had drawn a total of **$7.5 million** under the 2020 Loan Agreement and the full **$2.0 million** under the 2019 Loan Agreement[95](index=95&type=chunk)[96](index=96&type=chunk) - In lieu of interest, AgeX issued **common stock and warrants** to Juvenescence as consideration for the loan facilities[97](index=97&type=chunk)[100](index=100&type=chunk) - The 2019 Loan Agreement was amended in February 2021 to extend maturity to **February 14, 2022**, and increase the facility by **$4.0 million**, with an additional **$1.5 million** borrowed during Q2 2021[101](index=101&type=chunk)[102](index=102&type=chunk) - AgeX reimburses Juvenescence approximately **$280,000 annually** for its COO's services, with **$96,000** payable as of June 30, 2021[107](index=107&type=chunk) [6. Stockholders' Equity (Deficit)](index=26&type=section&id=6.%20Stockholders%27%20Equity%20%28Deficit%29) This section details AgeX Therapeutics' stockholders' equity (deficit), including authorized and outstanding shares, warrant issuances, and ATM offering proceeds - AgeX has **100,000,000 shares** of **$0.0001 par value** common stock authorized, with **37,937,132 shares** issued and outstanding as of June 30, 2021[109](index=109&type=chunk) - AgeX issued warrants to Juvenescence to purchase **3,362,098 shares** of common stock as consideration for **$7.5 million** in loans under the 2020 Loan Agreement[110](index=110&type=chunk) - Through an at-the-market (ATM) offering facility, AgeX raised approximately **$496,000 in gross proceeds** from common stock sales through June 30, 2021[112](index=112&type=chunk) Reconciliation of Changes in Stockholders' Equity (Deficit) (in thousands) | Item | Balance at Dec 31, 2020 | Issuance of common stock | Issuance of warrants | Stock-based compensation | Deconsolidation of LifeMap Sciences | Net loss | Balance at Jun 30, 2021 | | :-------------------------------- | :---------------------- | :----------------------- | :------------------- | :----------------------- | :---------------------------------- | :------- | :---------------------- | | Common Stock (Par Value) | $4 | $- | $- | $- | $- | $- | $4 | | Additional Paid-In Capital | $91,810 | $475 | $757 | $468 | $143 | $- | $93,379 | | Accumulated Deficit | $(97,073) | $- | $- | $- | $- | $(4,562) | $(101,635) | | Total Stockholders' Deficit | $(5,396) | $470 | $757 | $468 | $(22) | $(4,571) | $(8,294) | [7. Stock-Based Awards](index=29&type=section&id=7.%20Stock-Based%20Awards) This section provides details on AgeX Therapeutics' stock option and restricted stock unit activity, along with related stock-based compensation expenses Stock Option Activity (in thousands, except weighted average exercise price) | Item | Shares Available for Grant | Number of Options Outstanding | Number of RSUs Outstanding | Weighted Average Exercise Price | | :-------------------------------- | :------------------------- | :---------------------------- | :------------------------- | :------------------------------ | | December 31, 2020 | 1,046 | 2,854 | 28 | $2.51 | | Options granted | (568) | 568 | - | $1.46 | | Options forfeited, cancelled or expired | 40 | (40) | - | $3.00 | | Restricted stock units vested | - | - | (6) | - | | June 30, 2021 | 518 | 3,382 | 22 | $2.31 | | Options exercisable at June 30, 2021 | | 2,253 | | $2.51 | Stock-based Compensation Expense (in thousands) | Category | Three Months Ended June 30, 2021 | Three Months Ended June 30, 2020 | Six Months Ended June 30, 2021 | Six Months Ended June 30, 2020 | | :-------------------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Research and development | $15 | $15 | $31 | $48 | | General and administrative | $271 | $237 | $433 | $457 | | Total stock-based compensation expense – continued operations | $286 | $252 | $464 | $505 | | Stock-based compensation expense – discontinued operations | $4 | $7 | $4 | $14 | - Total stock-based compensation expense for continuing operations **increased by 13.5%** for the three months but **decreased by 8.1%** for the six months ended June 30, 2021, compared to prior year periods[121](index=121&type=chunk) [8. Income Taxes](index=30&type=section&id=8.%20Income%20Taxes) This section discusses AgeX Therapeutics' income tax provision, accounting for GILTI, and the valuation allowance for deferred tax assets - AgeX recorded **no income tax provision** for the three and six months ended June 30, 2021, due to domestic and foreign losses from continuing operations[124](index=124&type=chunk)[125](index=125&type=chunk) - The company accounts for **Global Intangible Low Tax Income (GILTI)** as a current period expense when incurred, with no GILTI included in income for the first six months of 2021 due to foreign entity losses[123](index=123&type=chunk) - A **full valuation allowance** has been established for all domestic deferred tax assets due to the uncertainty of realizing future tax benefits from net operating loss carryforwards[125](index=125&type=chunk) [9. Supplemental Cash Flow Information](index=30&type=section&id=9.%20Supplemental%20Cash%20Flow%20Information) This section provides supplemental disclosures regarding AgeX Therapeutics' non-cash investing and financing activities Supplemental Disclosures of Non-Cash Investing and Financing Activities (in thousands) | Item | Six Months Ended June 30, 2021 | Six Months Ended June 30, 2020 | | :------------------------------------------------ | :----------------------------- | :----------------------------- | | Cash paid during the period for interest | $11 | $11 | | Issuance of common stock upon vesting of restricted stock units | $11 | $13 | | Issuance of warrants for debt issuance | $757 | $689 | [10. Commitments and Contingencies](index=30&type=section&id=10.%20Commitments%20and%20Contingencies) This section outlines AgeX Therapeutics' commitments and contingencies, including lease agreements, PPP loan forgiveness, NYSE American listing compliance, and litigation status - AgeX's previous lease expired on December 31, 2020, relocating to a smaller office-only space with a base monthly rent of **$947** effective January 1, 2021[128](index=128&type=chunk)[131](index=131&type=chunk) - The **Paycheck Protection Program (PPP) loan of $432,952** obtained on April 13, 2020, was forgiven in full on February 19, 2021[137](index=137&type=chunk)[138](index=138&type=chunk) - AgeX regained compliance with **NYSE American listing standards** on April 15, 2021, after previously receiving a deficiency letter for not meeting certain equity and loss criteria[140](index=140&type=chunk)[141](index=141&type=chunk) - The company is **not aware of any litigation claims** likely to have a material adverse effect on its financial condition or results of operations[134](index=134&type=chunk) [11. Subsequent Events](index=34&type=section&id=11.%20Subsequent%20Events) This section discloses significant events that occurred after the reporting period, including additional borrowings and a change in the independent registered public accounting firm - On July 12, 2021, AgeX borrowed an additional **$1,000,000** under the amended 2019 Loan Agreement with Juvenescence[143](index=143&type=chunk) - OUM & Co. LLP, AgeX's independent registered public accounting firm, resigned on **July 15, 2021**, and WithumSmith + Brown PC was approved as the new firm on **July 20, 2021**[144](index=144&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=35&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) This section provides management's perspective on AgeX's financial condition and results, including critical accounting policies, COVID-19 impact, analysis of revenues, expenses, other income, income taxes, and liquidity, particularly concerning its going concern status [Critical Accounting Policies](index=35&type=section&id=Critical%20Accounting%20Policies) This section discusses management's reliance on estimates and assumptions in financial statements and confirms no significant changes to critical accounting policies - Management's financial statements rely on estimates and assumptions, with **no significant changes to critical accounting policies** during the six months ended June 30, 2021, except as disclosed in Note 2[147](index=147&type=chunk)[148](index=148&type=chunk) [Impact of COVID-19 Pandemic](index=35&type=section&id=Impact%20of%20COVID-19%20Pandemic) This section addresses the significant volatility and disruption caused by the COVID-19 pandemic, impacting operations, remote work, and research activities - The COVID-19 pandemic has caused **significant volatility and disruption**, leading to altered operations, remote work, and potential impacts on employee productivity and board meetings[149](index=149&type=chunk) - The pace of work on the Sponsored Research Agreement with the University of California at Irvine (UCI) for neural stem cell development was **slowed by COVID-19 safety procedures**[150](index=150&type=chunk) - The full extent of the pandemic's impact on business, operations, and financial results is **highly uncertain and difficult to predict**[151](index=151&type=chunk) [Results of Operations](index=37&type=section&id=Results%20of%20Operations) This section analyzes AgeX Therapeutics' financial performance, including detailed breakdowns of revenues, cost of sales, operating expenses, and other income Revenues and Cost of Sales (in thousands) | Item | Three Months Ended June 30, 2021 | Three Months Ended June 30, 2020 | Six Months Ended June 30, 2021 | Six Months Ended June 30, 2020 | | :---------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Grant revenues | $11 | $36 | $57 | $122 | | Other revenues | $26 | $9 | $36 | $12 | | Total revenues | $37 | $45 | $93 | $134 | | Cost of sales | $(13) | $(3) | $(16) | $(4) | | Gross profit | $24 | $42 | $77 | $130 | - Total revenues **decreased by 17.8%** for the three months and **30.6%** for the six months ended June 30, 2021, primarily due to a decrease in NIH grant revenues[155](index=155&type=chunk)[156](index=156&type=chunk) Operating Expenses (in thousands) | Item | Three Months Ended June 30, 2021 | Three Months Ended June 30, 2020 | Six Months Ended June 30, 2021 | Six Months Ended June 30, 2020 | | :-------------------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Research and development expenses | $481 | $935 | $805 | $2,156 | | General and administrative expenses | $1,748 | $1,475 | $3,770 | $3,350 | - Research and development expenses **decreased significantly by 48.6%** for the three months and **62.7%** for the six months ended June 30, 2021, due to staff layoffs and lab facility shutdown[159](index=159&type=chunk)[160](index=160&type=chunk)[161](index=161&type=chunk) - General and administrative expenses **increased by 18.5%** for the three months and **12.5%** for the six months ended June 30, 2021, driven by non-recurring projects, patent fees, consulting, and insurance, partially offset by reduced facilities rent[159](index=159&type=chunk)[162](index=162&type=chunk)[163](index=163&type=chunk)[164](index=164&type=chunk) - Other income, net, in 2021 primarily includes a **$437,000 gain** from the forgiveness of the PPP Loan[166](index=166&type=chunk) [Liquidity and Capital Resources](index=40&type=section&id=Liquidity%20and%20Capital%20Resources) This section discusses AgeX Therapeutics' liquidity position, capital resources, and its ability to continue as a going concern, highlighting accumulated deficit and funding requirements - AgeX had an **accumulated deficit of $101.6 million** as of June 30, 2021, and expects continued operating losses and negative cash flows, raising substantial doubt about its **going concern** ability[170](index=170&type=chunk)[171](index=171&type=chunk) - The company's cash, cash equivalents, potential additional loans from Juvenescence, and ATM offering proceeds are **not expected to be sufficient** for the next twelve months' funding requirements[171](index=171&type=chunk) - AgeX borrowed **$11.0 million** under loan agreements with Juvenescence as of June 30, 2021, with an additional **$1.0 million** drawn in July 2021, subject to Juvenescence's discretion[172](index=172&type=chunk)[143](index=143&type=chunk) - Net cash used in operating activities from continuing operations was **$4.2 million** for the six months ended June 30, 2021, primarily due to net loss offset by non-cash adjustments and working capital changes[177](index=177&type=chunk) - Net cash provided by investing activities from continuing operations was **$466,000**, stemming from cash proceeds received from the LifeMap Sciences merger[179](index=179&type=chunk) - Net cash provided by financing activities from continuing operations was **$4.2 million**, mainly from loan drawdowns from Juvenescence and proceeds from the ATM offering[181](index=181&type=chunk) [Item 3. Quantitative and Qualitative Disclosures about Market Risk](index=43&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) As a smaller reporting company, AgeX Therapeutics is **exempt from providing quantitative and qualitative disclosures about market risk** - AgeX Therapeutics, as a smaller reporting company, is **exempt from providing quantitative and qualitative disclosures about market risk**[184](index=184&type=chunk) [Item 4. Controls and Procedures](index=43&type=section&id=Item%204.%20Controls%20and%20Procedures) Management evaluated the effectiveness of the company's disclosure controls and procedures as of June 30, 2021, determining them effective with no material changes in internal control over financial reporting during the period - Management determined that **disclosure controls and procedures were effective** as of June 30, 2021[185](index=185&type=chunk) - **No material changes** in internal control over financial reporting occurred during the period covered by this Quarterly Report on Form 10-Q[186](index=186&type=chunk) PART II — OTHER INFORMATION [Item 1. Legal Proceedings](index=44&type=section&id=Item%201.%20Legal%20Proceedings) AgeX Therapeutics is **not currently involved in any material litigation or proceedings**, nor is it aware of any contemplated material legal actions - AgeX is **not presently involved in any material litigation or proceedings**, and no material litigation or proceedings are contemplated[188](index=188&type=chunk) [Item 1A. Risk Factors](index=44&type=section&id=Item%201A.%20Risk%20Factors) This section reiterates AgeX's business faces various risks, particularly the need for additional financing to continue as a **going concern**, with its accumulated deficit and projected cash flows raising substantial doubt about future financial obligations - AgeX needs **additional financing** to execute its operating plan and continue as a **going concern**, as current cash and available credit are insufficient for the next twelve months[189](index=189&type=chunk) - The company had an **accumulated deficit of $101.6 million** as of June 30, 2021, and expects continued operating losses and negative cash flows[190](index=190&type=chunk) - The ability to obtain necessary capital is **uncertain**, and failure could force delays, reductions, or elimination of R&D activities, or prevent the company from continuing as a **going concern**[190](index=190&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=44&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) AgeX sold **242,200 shares** of common stock through an ATM offering, generating **$495,708 in gross proceeds** and **$480,790 in net proceeds**, primarily used for working capital including legal, tax, audit fees, insurance, and consulting - AgeX sold **242,200 shares** of common stock in an ATM Offering through Chardan Capital Markets LLC during the six months ended June 30, 2021[193](index=193&type=chunk) ATM Offering Proceeds and Expenses (Six Months Ended June 30, 2021) | Item | Amount ($) | | :------------------- | :----------- | | Gross proceeds | 495,708 | | Sales Agent fees | 14,871 | | Other expenses | 47 | | Total expenses | 14,918 | | Net proceeds | 480,790 | - Net proceeds from the ATM Offering were used for working capital, including legal, tax, and audit professional fees (**$224,300**), insurance premiums (**$103,700**), consulting fees (**$58,400**), director compensation (**$37,500**), and other operating expenses (**$56,800**)[196](index=196&type=chunk) [Item 3. Default Upon Senior Securities](index=46&type=section&id=Item%203.%20Default%20Upon%20Senior%20Securities) AgeX Therapeutics reported **no defaults upon senior securities** - There were **no defaults upon senior securities**[198](index=198&type=chunk) [Item 4. Mine Safety Disclosures](index=46&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is **not applicable** to AgeX Therapeutics - Mine Safety Disclosures are **not applicable** to AgeX Therapeutics[199](index=199&type=chunk) [Item 5. Other Information](index=46&type=section&id=Item%205.%20Other%20Information) AgeX Therapeutics disclosed a subsequent event where it borrowed an additional **$1,000,000** under the amended 2019 Loan Agreement with Juvenescence on July 12, 2021 - On July 12, 2021, AgeX borrowed an additional **$1,000,000** under the amended 2019 Loan Agreement with Juvenescence[200](index=200&type=chunk) [Item 6. Exhibits](index=46&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including organizational documents, certifications, and various Inline XBRL documents - Exhibits include **organizational documents**, **certifications**, and **Inline XBRL documents**[201](index=201&type=chunk) [SIGNATURES](index=47&type=section&id=SIGNATURES) The report is duly signed on behalf of AgeX Therapeutics, Inc. by its Chief Executive Officer, Michael D. West, and Chief Financial Officer, Andrea E. Park, on **August 13, 2021** - The report was signed by Michael D. West, Chief Executive Officer, and Andrea E. Park, Chief Financial Officer, on **August 13, 2021**[204](index=204&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission file number 1-38519 AgeX Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of i ...